Novartis is delighted to announce it has developed a new therapy drug to ease the symptoms of irritable skin condition, psoriasis.
The pharma company has presented new clinical data for its drug, secukinumab, claiming its benefits include providing clearer skin for sufferers.
Discussions at the European Association of Dermatology and Venereology Congress have shown the drug has resulted in higher rates of clear or almost clear skin at week 12 versus placebo, following analysis of phase III of its studies.
Phase III results looked promising for people with mild or severe psoriasis. There were positive trends for people who had sever psoriasis at the start of treatment, who also showed better health-related quality of life following use of the drug.
Global Head of Development at Novartis Pharmaceuticals, Mr Vasant Narasimhan, said, “With global regulatory approvals anticipated shortly, we hope to bring secukinumab to patients living with this debilitating disease, which impacts much more than their skin.”
The drug is also known as AIN457 and became the first ever IL-17A inhibitor to meet its primary endpoint in two phase III studies for psoriatic arthritis.
Secukinumab has been submitted for regulatory review in both the US and EU, and is awaiting a response.